Pharvaris (PHVS)
Develops oral deucrictibant formulations to treat and prevent hereditary angioedema attacks.
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 92.22% | 64.44M ADS | |
|---|---|---|---|
| 130 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Other | ≈ 7.78% | 5.44M ADS | |
| remainder | |||
69.88M ADS as of Sep 15, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2023 annual report; nothing newer is on file here.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
130 holders · 64.44M shares · 23 new positions · 72 increased · 34 reduced · 9 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 6.57M | 9.40% | +280.8K | Aug 13, 2026 |
| General Atlantic, L.P. | 6.55M | 9.37% | −1.48M | Aug 14, 2026 |
| Foresite Capital Management Iv, LLC | 4.78M | 6.84% | 0 | Aug 14, 2026 |
| Venbio Partners LLC | 4.64M | 6.64% | +4.1K | Aug 14, 2026 |
| Viking Global Investors LP | 3.65M | 5.23% | 0 | Aug 14, 2026 |
| Eqt Fund Management S.A R.L. | 3.42M | 4.90% | 0 | Aug 13, 2026 |
| Deerfield Management Company, L.P. (Series C) | 3.38M | 4.83% | +250.0K | Aug 14, 2026 |
| Bain Capital Life Sciences Investors, LLC | 2.68M | 3.83% | 0 | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Viking Global Investors LP | 5.60% | 3.65M | 13G | May 15, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 17, 2026 | Johannes Gerardus Christiaan Petrus Schikandirector | Sale | 200,000 | $35.00 | 115,167 |
| Sep 17, 2026 | Peng Luofficer: President | Sale | 100,000 | $35.00 | 64,953 |
| Sep 17, 2026 | Robert Glassmandirector | Sale | 14,493 | $38.56 | 10,500 |
| Sep 17, 2026 | Elisabeth Bjorkdirector | Sale | 52,500 | $37.89 | 15,167 |
| Sep 17, 2026 | Anne Lesageofficer: Chief Early Development | Sale | 20,000 | $38.27 | 73,969 |
| Sep 15, 2026 | Stefan Andreas Abeleofficer: Chief Technical Ops Officer | Sale · 2 lots | 46,400 | $38.17 | 39,068 |
| Sep 15, 2026 | Robert Glassmandirector | Sale | 8,667 | $38.27 | 10,500 |
| Sep 15, 2026 | Wim Souverijnsofficer: Chief Commercial Officer | Sale | 6,090 | $38.99 | 39,021 |
| Sep 14, 2026 | Wim Souverijnsofficer: Chief Commercial Officer | Sale | 20,000 | $39.31 | 45,111 |
| Sep 11, 2026 | Peng Luofficer: President | Sale | 15,000 | $40.13 | 65,179 |
House and Senate disclosures
Not reported.